Investigating the effect of different targets in deep brain stimulation on symptoms of Parkinson's disease using a mean-field model of the basal ganglia-thalamocortical system

Author(s):  
Alireza Nahvi ◽  
Fariba Bahrami
2012 ◽  
Vol 12 (02) ◽  
pp. 1240004 ◽  
Author(s):  
ALIREZA NAHVI ◽  
FARIBA BAHRAMI ◽  
SAMIRA HEMMATI

In this paper, we investigated effects of deep brain stimulation (DBS) on Parkinson's disease (PD) when different target sites in the basal ganglia are stimulated. The targets which are investigated are subthalamic nucleus (STN), globus pallidus interna (GPi), and globus pallidus externa (GPe). For this purpose we used a computational model of the basal ganglia-thalamocortical system (BGTCS) with parameters calculated for mean field. This model is able to reproduce both the normal and Parkinsonian activities of basal ganglia, thalamus and cortex in a unified structure. In the present study, we used a mean-field model of the BGTCS, allowing a more complete framework to simulate DBS and to interpret its effects in the BGTCS. Our results suggest that DBS in the STN and GPe could restore the thalamus relay activity, while DBS in the GPi could inhibit it. Our results are compatible with the experimental and the clinical outcomes about the effects of DBS of different targets.


Brain ◽  
2008 ◽  
Vol 131 (12) ◽  
pp. 3410-3420 ◽  
Author(s):  
P. Crenna ◽  
I. Carpinella ◽  
L. Lopiano ◽  
A. Marzegan ◽  
M. Rabuffetti ◽  
...  

2019 ◽  
Vol 116 (52) ◽  
pp. 26259-26265 ◽  
Author(s):  
Jerrold L. Vitek ◽  
Luke A. Johnson

Parkinson’s disease (PD) is a progressive neurodegenerative movement disorder affecting over 10 million people worldwide. In the 1930s and 1940s there was little understanding regarding what caused PD or how to treat it. In a desperate attempt to improve patients’ lives different regions of the neuraxis were ablated. Morbidity and mortality were common, but some patients’ motor signs improved with lesions involving the basal ganglia or thalamus. With the discovery ofl-dopa the advent of medical therapy began and surgical approaches became less frequent. It soon became apparent, however, that medical therapy was associated with side effects in the form of drug-induced dyskinesia and motor fluctuations and surgical therapies reemerged. Fortunately, during this time studies in monkeys had begun to lay the groundwork to understand the functional organization of the basal ganglia, and with the discovery of the neurotoxin MPTP a monkey model of PD had been developed. Using this model scientists were characterizing the physiological changes that occurred in the basal ganglia in PD and models of basal ganglia function and dysfunction were proposed. This work provided the rationale for the return of pallidotomy, and subsequently deep brain stimulation procedures. In this paper we describe the evolution of these monkey studies, how they provided a greater understanding of the pathophysiology underlying the development of PD and provided the rationale for surgical procedures, the search to understand mechanisms of DBS, and how these studies have been instrumental in understanding PD and advancing the development of surgical therapies for its treatment.


2014 ◽  
Vol 2 (5) ◽  
pp. 149-155 ◽  
Author(s):  
Peter Zsigmond ◽  
Maria Nord ◽  
Anita Kullman ◽  
Elin Diczfalusy ◽  
Karin Wårdell ◽  
...  

2020 ◽  
Vol 91 (8) ◽  
pp. e6.1-e6
Author(s):  
Peter Brown

Professor Peter Brown is Professor of Experimental Neurology and Director of the Medical Research Council Brain Network Dynamics Unit at the University of Oxford. Prior to 2010 he was a Professor of Neurology at University College London.For decades we have had cardiac pacemakers that adjust their pacing according to demand and yet therapeutic adaptive stimulation approaches for the central nervous system are still not clinically available. Instead, to treat patients with advanced Parkinson’s disease we stimulate the basal ganglia with fixed regimes, unvarying in frequency or intensity. Although effective, this comes with side-effects and in terms of sophistication this treatment approach could be compared to having central heating system on all the time, regardless of temperature. This talk will describe recent steps being taken to define the underlying circuit dysfunction in Parkinson’s and to improve deep brain stimulation by controlling its delivery according to the state of pathological activity.Evidence is growing that motor symptoms in Parkinson’s disease are due, at least in part, to excessive synchronisation between oscillating neurons. Recordings confirm bursts of oscillatory synchronisation in the basal ganglia centred around 20 Hz. The bursts of 20 Hz activity are prolonged in patients withdrawn from their usual medication and the dominance of these long duration bursts negatively correlates with motor impairment. Longer bursts attain higher amplitudes, indicative of more pervasive oscillatory synchronisation within the neural circuit. In contrast, in heathy primates and in treated Parkinson’s disease bursts tend to be short. Accordingly, it might be best to use closed-loop controlled deep brain stimulation to selectively terminate longer, bigger, pathological beta bursts to both save power and to spare the ability of underlying neural circuits to engage in more physiological processing between long bursts. It is now possible to record and characterise bursts on-line during stimulation of the same site and trial adaptive stimulation. Thus far, this has demonstrated improvements in efficiency and side-effects over conventional continuous stimulation, with at least as good symptom control in Parkinsonian patients.


2010 ◽  
Vol 103 (2) ◽  
pp. 962-967 ◽  
Author(s):  
Jonathan D. Carlson ◽  
Daniel R. Cleary ◽  
Justin S. Cetas ◽  
Mary M. Heinricher ◽  
Kim J. Burchiel

Two broad hypotheses have been advanced to explain the clinical efficacy of deep brain stimulation (DBS) in the subthalamic nucleus (STN) for treatment of Parkinson's disease. One is that stimulation inactivates STN neurons, producing a functional lesion. The other is that electrical stimulation activates the STN output, thus “jamming” pathological activity in basal ganglia-corticothalamic circuits. Evidence consistent with both concepts has been adduced from modeling and animal studies, as well as from recordings in patients. However, the stimulation parameters used in many recording studies have not been well matched to those used clinically. In this study, we recorded STN activity in patients with Parkinson's disease during stimulation delivered through a clinical DBS electrode using standard therapeutic stimulus parameters. A microelectrode was used to record the firing of a single STN neuron during DBS (3–5 V, 80–200 Hz, 90- to 200-μs pulses; 33 neurons/11 patients). Firing rate was unchanged during the stimulus trains, and the recorded neurons did not show prolonged (s) changes in firing rate on termination of the stimulation. However, a brief (∼1 ms), short-latency (6 ms) postpulse inhibition was seen in 10 of 14 neurons analyzed. A subset of neurons displayed altered firing patterns, with a predominant shift toward random firing. These data do not support the idea that DBS inactivates the STN and are instead more consistent with the hypothesis that this stimulation provides a null signal to basal ganglia-corticothalamic circuitry that has been altered as part of Parkinson's disease.


Sign in / Sign up

Export Citation Format

Share Document